New study shows maternal RSV vaccine is highly effective

A groundbreaking new study from the UK Health Security Agency has confirmed that the maternal RSV vaccine is a game-changer for infant health.

By analyzing data from nearly 300,000 babies, researchers found that when mothers receive the vaccine at least two weeks before birth, the risk of their newborns requiring hospital care for RSV drops by 81.3%.

For optimal protection, administering the vaccine at least four weeks before delivery boosts effectiveness to nearly 85%.

The vaccine works by triggering the mother's immune system to create antibodies, which are then passed to the fetus via the placenta, granting the infant vital passive immunity.

As RSV remains a leading cause of severe respiratory issues like bronchiolitis in young infants, this real-world evidence proves that maternal vaccination is a highly successful strategy for reducing hospitalizations and keeping our most vulnerable newborns safe during their critical first few months of life.